AR029464A1 - Metodos para el tratamiento de la diabetes - Google Patents
Metodos para el tratamiento de la diabetesInfo
- Publication number
- AR029464A1 AR029464A1 ARP010100326A ARP010100326A AR029464A1 AR 029464 A1 AR029464 A1 AR 029464A1 AR P010100326 A ARP010100326 A AR P010100326A AR P010100326 A ARP010100326 A AR P010100326A AR 029464 A1 AR029464 A1 AR 029464A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- neurotoxin
- treatment
- methods
- hyperinsulinemic
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 101710138657 Neurotoxin Proteins 0.000 abstract 3
- 239000002581 neurotoxin Substances 0.000 abstract 3
- 231100000618 neurotoxin Toxicity 0.000 abstract 3
- 230000000910 hyperinsulinemic effect Effects 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 229940053031 botulinum toxin Drugs 0.000 abstract 1
- -1 for example Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 210000000331 sympathetic ganglia Anatomy 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/491,420 US6337075B1 (en) | 2000-01-11 | 2000-01-26 | Methods for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029464A1 true AR029464A1 (es) | 2003-07-02 |
Family
ID=23952146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100326A AR029464A1 (es) | 2000-01-26 | 2001-01-25 | Metodos para el tratamiento de la diabetes |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6337075B1 (enExample) |
| EP (1) | EP1250146B1 (enExample) |
| JP (1) | JP4851042B2 (enExample) |
| AR (1) | AR029464A1 (enExample) |
| AT (1) | ATE257013T1 (enExample) |
| AU (1) | AU2001231104A1 (enExample) |
| DE (1) | DE60101669T2 (enExample) |
| DK (1) | DK1250146T3 (enExample) |
| ES (1) | ES2211765T3 (enExample) |
| TW (1) | TWI233806B (enExample) |
| WO (1) | WO2001054711A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| ES2237551T3 (es) * | 2000-02-08 | 2005-08-01 | Allergan, Inc. | Composiciones farmaceuticas que contienen toxina botulinica. |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US6486127B1 (en) * | 2001-05-23 | 2002-11-26 | Insmed, Incorporated | Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof |
| US6492339B1 (en) * | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
| US6984375B2 (en) * | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| MXPA04004543A (es) | 2001-11-15 | 2005-03-31 | Micro Algae Corp | Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal. |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| BRPI0510759A (pt) * | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método de facilitar a cura de um ferimento |
| EP1796676B1 (en) * | 2004-05-07 | 2016-03-09 | Phytotox Limited | Transdermal administration of phycotoxins |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| WO2006130161A2 (en) * | 2004-07-21 | 2006-12-07 | The Cornell Research Foundation, Inc. | Therapeutic compounds derived from spider venom and their method of use |
| EP1982997B1 (en) | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| EP1861419B1 (en) | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| WO2009002437A2 (en) * | 2007-06-25 | 2008-12-31 | The Board Of Regents Of The University Of Texas System | Neurotoxin theraphy for postprandial hyperglycemia |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| FR2972928B1 (fr) * | 2011-03-25 | 2013-11-29 | Urgo Lab | Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| CN109790204A (zh) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | 杂合神经毒素 |
| WO2019162696A1 (en) | 2018-02-26 | 2019-08-29 | Ipsen Biopharm Limited | Use of ultrasound to guide injection of non-cytotoxic protease |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| WO2021231668A1 (en) | 2020-05-15 | 2021-11-18 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| KR102520625B1 (ko) | 2019-10-18 | 2023-04-12 | 펜랜드 파운데이션 | 치료에 사용하기 위한 보톨리늄 독소 |
| WO2021231666A1 (en) | 2020-05-15 | 2021-11-18 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US11738071B2 (en) | 2021-07-12 | 2023-08-29 | Penland Foundation | Treatment of acute and chronic kidney disease |
| US12636343B2 (en) | 2019-10-18 | 2026-05-26 | Penland Foundation | Treatment of vestibular vertigo using botulinum toxins |
| US20220143158A1 (en) * | 2020-09-18 | 2022-05-12 | Vanderbilt University | Duodenal administration of botulinum toxin |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| WO2023287728A1 (en) * | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| DE69434535T2 (de) | 1993-12-28 | 2006-07-20 | Allergan, Inc., Irvine | Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| AU6034396A (en) | 1995-06-06 | 1996-12-24 | L. Bruce Pearce | Improved compositions and methods for chemodenervation using neurotoxins |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
-
2000
- 2000-01-26 US US09/491,420 patent/US6337075B1/en not_active Expired - Fee Related
-
2001
- 2001-01-19 TW TW090101295A patent/TWI233806B/zh not_active IP Right Cessation
- 2001-01-24 EP EP01903262A patent/EP1250146B1/en not_active Expired - Lifetime
- 2001-01-24 AU AU2001231104A patent/AU2001231104A1/en not_active Abandoned
- 2001-01-24 JP JP2001554694A patent/JP4851042B2/ja not_active Expired - Lifetime
- 2001-01-24 DK DK01903262T patent/DK1250146T3/da active
- 2001-01-24 AT AT01903262T patent/ATE257013T1/de not_active IP Right Cessation
- 2001-01-24 DE DE60101669T patent/DE60101669T2/de not_active Expired - Lifetime
- 2001-01-24 ES ES01903262T patent/ES2211765T3/es not_active Expired - Lifetime
- 2001-01-24 WO PCT/US2001/002273 patent/WO2001054711A2/en not_active Ceased
- 2001-01-25 AR ARP010100326A patent/AR029464A1/es unknown
- 2001-10-03 US US09/972,702 patent/US6416765B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK1250146T3 (da) | 2004-04-26 |
| AU2001231104A1 (en) | 2001-08-07 |
| WO2001054711A3 (en) | 2002-02-21 |
| US6416765B1 (en) | 2002-07-09 |
| EP1250146A2 (en) | 2002-10-23 |
| TWI233806B (en) | 2005-06-11 |
| US20020031529A1 (en) | 2002-03-14 |
| JP4851042B2 (ja) | 2012-01-11 |
| DE60101669D1 (de) | 2004-02-05 |
| DE60101669T2 (de) | 2004-10-21 |
| ES2211765T3 (es) | 2004-07-16 |
| US6337075B1 (en) | 2002-01-08 |
| JP2003520822A (ja) | 2003-07-08 |
| EP1250146B1 (en) | 2004-01-02 |
| ATE257013T1 (de) | 2004-01-15 |
| WO2001054711A2 (en) | 2001-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001054711A3 (en) | Use of neurotoxins for treating diabetes | |
| DK1638586T3 (da) | Synergistisk sammensætning til behandling af diabetes mellitus | |
| BR0016962A (pt) | Métodos para o tratamento de distúrbios pancreáticos | |
| AR032349A1 (es) | Uso de neurotoxinas para preparar composiciones farmaceuticas de aplicacion en el tratamiento de trastornos del movimiento | |
| DK1521593T3 (da) | Transdermale botulinumtoksinforbindelser | |
| TW200503751A (en) | Methods for treating sinus headache | |
| MXPA03002576A (es) | Metodos para tratar lesiones musculares. | |
| AR028939A1 (es) | Metodo para tratar un desorden pancreatico con una neurotoxina | |
| AR049955A1 (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos | |
| AR030406A1 (es) | Uso de neurotoxinas para la preparacion de composiciones farmaceuticas , de aplicacion en la preparacion de composiciones para el tratamiento de desordenes paratiroidicos | |
| DK0605501T5 (da) | Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese | |
| AR069806A1 (es) | Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales | |
| MX9306295A (es) | Composiciones farmaceuticas para tratar sintomas de resfriado. | |
| DK1280541T3 (da) | Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse af eller behandling af fordöjelsesforstyrrelser | |
| NO20054580L (no) | Behandling av sinusitisrelatert kronisk ansiktssmerte og hodepine med botulinumtoksin | |
| CL2003002785A1 (es) | Uso de 4,5,6,7-tetrahidroisoxazolo(5,4-c)piridin-3-ol (thip) para preparar una composicion farmaceutica util para tratar un trastorno del sueno. | |
| WO2006138059A3 (en) | Treatment of autoimmune disorders with a neurotoxin | |
| BR0315979A (pt) | Formulação oral de toxina botulìnica e uso da mesma para tratar úlceras pépticas e doença de refluxo gastroesofágico | |
| DE60310400D1 (de) | Botulinustoxine zur behandlung von priapismus | |
| JP2003519666A5 (enExample) | ||
| MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
| UY26678A1 (es) | El uso de composiciones a base de antibióticos de azalidos para tratar o prevenir una infección bacteriana o protozoaria en mamíferos | |
| AR050673A1 (es) | Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno | |
| CA2561588A1 (en) | Pressure sore treatment | |
| AR048811A1 (es) | Uso de toxina botulinica en la preparacion de un medicamento para evitar el crecimiento del vello |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |